NCT01641133View on ClinicalTrials.gov

Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™

PHASE3CompletedINTERVENTIONAL
Enrollment

457

Participants

Timeline

Start Date

September 4, 2012

Primary Completion Date

July 15, 2013

Study Completion Date

May 7, 2014

Conditions
Infections, StreptococcalStreptococcus Pneumoniae Vaccines
Interventions
BIOLOGICAL

Synflorix (3-Dose)

3 doses administered intramuscularly

BIOLOGICAL

Synflorix (2-Dose)

2 doses administered intramuscularly

BIOLOGICAL

Synflorix (Single Dose)

1 dose administered intramuscularly

BIOLOGICAL

Prevenar 13 (Single Dose)

1 dose administered intramuscularly

BIOLOGICAL

Prevenar 13 (2-Dose)

2 doses administered intramuscularly

Trial Locations (3)

62210

GSK Investigational Site, Cuernavaca

64460

GSK Investigational Site, Monterrey

04530

GSK Investigational Site, México

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY